CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CRLNYSE · SIC 8731
$224.35
↓ -2.1%Jul 17 close · end-of-day
Price
1Y↑ +44.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$11.0B
Enterprise Value
$13.5B
P/E
—
P/S
2.7
P/B
3.7
EV/EBITDA
32.0
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$4.0B
Net Income (TTM)
-$184.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
1.8%
Net Margin
-4.6%
ROE
-6.3%
ROIC
1.0%
Debt / Equity
0.9
Net Cash
-$2.5B
Return 1Y
+43.2%
Company profile
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services. The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies. The Manufacturing segment provides in vitro testing of sterile and non-sterile pharmaceuticals and consumer products.
- CEO
- James C. Foster
- Sector
- Services
- Industry
- Business Services
- Employees
- 21,400
- Headquarters
- Massachusetts
- Website
- criver.com
Management & directors
- Girshick BirgitCorporate Executive VP & COO
- Parisotto Shannon MCEVP, Disc & Safety Assessment
- Creamer Victoria LEVP & Chief People Officer
- Knell Michael GunnarCSVP, CAO, Interim CFO
- Laplume Joseph WEVP, Corp Strategy & Develop
- Mintz MarkEVP, Chief Information Officer
- Coleman GlennEVP & Chief Financial Officer
- Foster James CChairman, President and CEO
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-08-06
CRL Q1 2026 Earnings
Period ends 2026-03-28
MetricActualYoY
Revenue$995.8M↑ +1.2%
Diluted EPS-$0.30↓ -160.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.9B | $3.5B | $4.0B | $4.1B | $4.0B | $4.0B |
| Gross profit | — | — | — | — | — | — |
| Operating income | $432.7M | $589.9M | $651.0M | $617.3M | $227.3M | $25.2M |
| Net income | $364.3M | $391.0M | $486.2M | $474.6M | $22.2M | -$144.3M |
| Diluted EPS | $7.20 | $7.60 | $9.48 | $9.22 | $0.20 | -$2.91 |
| Operating cash flow | $546.6M | $760.8M | $619.6M | $683.9M | $734.6M | $737.6M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 14.8% | 16.7% | 16.4% | 14.9% | 5.6% | 0.6% |
| Net margin | 12.5% | 11.0% | 12.2% | 11.5% | 0.5% | -3.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0B | $1.0B | $1.0B | $984.2M | $1.0B | $1.0B | $994.2M | $995.8M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $151.7M | $117.4M | -$167.7M | $74.7M | $100.1M | $133.8M | -$283.4M | $119.9M |
| Net income | $94.1M | $69.7M | -$214.5M | $25.5M | $52.3M | $54.4M | -$276.6M | -$14.8M |
| Diluted EPS | $1.74 | $1.33 | -$4.17 | $0.50 | $1.06 | $1.10 | -$5.57 | -$0.30 |
| Operating cash flow | $193.5M | $251.8M | $159.4M | $171.7M | $204.6M | $213.8M | $147.5M | $41.1M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 14.8% | 11.6% | -16.7% | 7.6% | 9.7% | 13.3% | -28.5% | 12.0% |
| Net margin | 9.2% | 6.9% | -21.4% | 2.6% | 5.1% | 5.4% | -27.8% | -1.5% |
Company news
Jul 17, 2026
Jul 16, 2026
- 4d agoAbbott Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-marketfinance.yahoo.com
- 4d agoIs Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year?finance.yahoo.com
- 4d agoDoes Arovella CAR-iNKT NGS Partnership Deepen Charles River’s Cell Therapy Moat or Stretch CRL Too Thin?finance.yahoo.com
Jul 15, 2026
Jul 14, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-29 | FOSTER JAMES C | Sale | 75,000 | $225.00 | $16.9M | filing |
| 2026-06-05 | FOSTER JAMES C | Gift | 153,361 | $0.00 | $0.00 | filing |
| 2026-06-05 | FOSTER JAMES C | Gift | 20,000 | $0.00 | $0.00 | filing |
| 2026-06-05 | FOSTER JAMES C | Gift | 10,000 | $0.00 | $0.00 | filing |
| 2026-06-05 | Girshick Birgit· Chief Executive Officer | Gift | 3,386 | $0.00 | $0.00 | filing |
| 2026-06-05 | Parisotto Shannon M· CEVP, Disc & Safety Assessment | Gift | 1,529 | $0.00 | $0.00 | filing |
| 2026-06-02 | Barg Steven | Award | 422 | $174.79 | $73,761.38 | filing |
| 2026-05-31 | Girshick Birgit· Chief Executive Officer | Tax withholding | 378 | $180.71 | $68,308.38 | filing |
| 2026-05-31 | LaPlume Joseph W· EVP, Corp Strategy & Develop | Tax withholding | 235 | $180.71 | $42,466.85 | filing |
| 2026-05-31 | Creamer Victoria L· EVP & Chief People Officer | Tax withholding | 194 | $180.71 | $35,057.74 | filing |
| 2026-05-31 | Parisotto Shannon M· CEVP, Disc & Safety Assessment | Tax withholding | 170 | $180.71 | $30,720.70 | filing |
| 2026-05-31 | Mintz Mark· EVP, Chief Information Officer | Tax withholding | 64 | $180.71 | $11,565.44 | filing |
| 2026-05-31 | Knell Michael Gunnar· SVP, Finance and CAO | Tax withholding | 48 | $180.71 | $8,674.08 | filing |
| 2026-05-30 | FOSTER JAMES C | Tax withholding | 1,596 | $180.71 | $288,413.16 | filing |
| 2026-05-30 | Girshick Birgit· Chief Executive Officer | Tax withholding | 1,204 | $180.71 | $217,574.84 | filing |
| 2026-05-30 | LaPlume Joseph W· EVP, Corp Strategy & Develop | Tax withholding | 744 | $180.71 | $134,448.24 | filing |
| 2026-05-30 | Creamer Victoria L· EVP & Chief People Officer | Tax withholding | 616 | $180.71 | $111,317.36 | filing |
| 2026-05-30 | Parisotto Shannon M· CEVP, Disc & Safety Assessment | Tax withholding | 551 | $180.71 | $99,571.21 | filing |
| 2026-05-30 | Mintz Mark· EVP, Chief Information Officer | Tax withholding | 305 | $180.71 | $55,116.55 | filing |
| 2026-05-30 | Knell Michael Gunnar· SVP, Finance and CAO | Tax withholding | 152 | $180.71 | $27,467.92 | filing |
| 2026-05-29 | Girshick Birgit· Chief Executive Officer | Award | 9,961 | $180.71 | $1.8M | filing |
| 2026-05-29 | Coleman Glenn· EVP & Chief Financial Officer | Award | 6,640 | $180.71 | $1.2M | filing |
| 2026-05-29 | LaPlume Joseph W· EVP, Corp Strategy & Develop | Award | 5,257 | $180.71 | $949,992.47 | filing |
| 2026-05-29 | Creamer Victoria L· EVP & Chief People Officer | Award | 5,135 | $180.71 | $927,945.85 | filing |
| 2026-05-29 | Parisotto Shannon M· CEVP, Disc & Safety Assessment | Award | 4,361 | $180.71 | $788,076.31 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.